Bloomberg Intelligence cover image

Eli Lilly, Morphic Deal, Delta Earnings

Bloomberg Intelligence

00:00

Eli Lilly's Acquisition Strategy and Industry Innovations

The chapter explores Eli Lilly's $3.2 billion acquisition of Morphic to enhance their immunology franchise by focusing on new technologies and early stage deals. It discusses the pharmaceutical industry's trend of acquiring therapeutics through M&A deals, highlighting Lilly's strategy of bolt-on acquisitions in various therapeutic areas over the past five years. The episode also touches on advancements in different disease fields like obesity, oncology, inflammation, and neurodegenerative diseases, as well as the challenges in developing preventative drugs for complex conditions such as Alzheimer's.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app